FERRIC CITRATE

Absorption

Ferric iron has been shown to have inferior bioavailability to ferrous iron preparations. Tetraferric tricitrate decahydrate has 19% the bioavailability of ferrous ascorbate.

Toxicity

Patients experiencing an overdose of iron may present with nausea, vomiting, abdominal pain, diarrhea, fluid and blood loss, hypovolemia, hematemesis, perforation, and peritonitis. Mild overdoses can be treated with symptomatic and supportive measures. More severe overdoses may require more intense treatment including chelating agents, and intravenous fluids. Activated charcoal is not expected to be beneficial in the case of iron overdose.
The acute oral LD50 in rats is 1487mg/kg and in mice is 1520mg/kg. The acute dermal LD50 in rabbits is 2000mg/kg.

Chemical properties

red to brown powder

The Uses of FERRIC CITRATE

Ferric Citrate is a nutrient supplement that is prepared from reac- tion of citric acid with ferric hydroxide. it is a compound of indefi- nite ratio of citric acid and iron. the ingredient may be used in infant formula. it is also termed iron (iii) citrate.

The Uses of FERRIC CITRATE

Medicine, blueprint paper.

Indications

Tetraferric tricitrate decahydrate is indicated to control serum phosphorous in adults with chronic kidney disease who require dialysis. Tetraferric tricitrate decahydrate is also indicated to treat iron deficiency anemia in adults with chronic kidney disease who are not on dialysis.

Background

Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease.
Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.

Definition

ChEBI: Iron(III) citrate is an iron chelate resulting from the combination of iron(3+) and citrate(3-). It has a role as an anti-anaemic agent and a nutraceutical. It contains a citrate(3-) and an iron(3+).

Flammability and Explosibility

Not classified

Pharmacokinetics

Tetraferric tricitrate decahydrate is an iron containing product indicated to treat iron deficiency anemia and hyperphosphatemia. It has a wide therapeutic index, as doses can be varied significantly between patients. Tetraferric tricitrate decahydrate has a long duration of action in the treatment of iron deficiency anemia, due to the slow loss of iron from the body, and a moderate duration of action in the treatment of hyperphosphatemia, due to its action being dependant on residence time in the gastrointestinal tract. Patients should be counselled regarding the risk of iron overload.

Safety Profile

When heated to decomposition it emits acrid smoke and irritating fumes.

Metabolism

Ferric cation is converted to ferrous iron by duodenal cytochrome B reductase. The heavy chain ferritin may also convert ferric iron to ferrous iron